AI Article Synopsis
- In some newborns with specific heart defects, Prostaglandin E(1) (PGE1) therapy may be required for over two weeks, but this can cause various side effects.
- A study reviewed nine patients on prolonged PGE1, finding high white blood cell counts, feeding issues, and the development of cortical hyperostosis linked to larger doses.
- The authors emphasize the need for regular monitoring of fluid and electrolyte levels, noting a stronger correlation between higher PGE1 doses and electrolyte disturbances compared to other effects.
Article Abstract
Background: In some neonates suffering from ductus arteriosus dependent congenital heart defect, a Prostaglandin E(1) (PGE1) therapy longer than 2 weeks may be needed. However, PGE1 analogue compounds may produce several adverse effects.
Methods: The authors retrospectively analyzed the data of nine patients who underwent a PGE1 treatment lasting longer than 14 days.
Results: The leukocyte count of the patients remained high throughout the treatment period, and the proportion of neutrophils was over 50%. Transient feeding difficulty and abdominal distension, and possible signs of gastric-outlet obstruction, were observed in two cases. In the case of three patients, cortical hyperostosis developed after different cumulative doses (1584, 3384 and 4320 microg). Significant correlations were found between the doses of PGE1 and serum K(+) levels (r=-0.770, P < 0.05) and between the blood standard bicarbonate levels and PGE1 doses (r= 0.889, P < 0.01). Bartter syndrome-like condition developed in those three patients who received the largest cumulative doses.
Conclusions: Fluid-electrolyte parameters must be controlled frequently in the case of each patient treated with PGE1 for longer than 2 weeks. Although the dose, the length of the therapy and individual susceptibility may be equally important, fluid-electrolyte disturbances and the development of pseudo-Bartter syndrome seem to be more dose-dependent than cortical hyperostosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1442-200X.2007.02380.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vitamin D levels and morbidity and mortality in very low birth weight preterm infants.
Andes Pediatr
August 2023
Departamento de Pediatría, Facultad de Medicina, Universidad de Concepción, Concepción, Chile.
Unlabelled: Very low birth weight (VLBW) preterm newborns lack some nutrients such as vitamin D (VD), which is important in the function and development of different systems.
Objective: To evaluate serum levels of 25-OH-VD in VLBW newborns and to describe the possible association between its deficit and frequent morbidities in this population.
Patients And Methods: Cross-sectional study of VLBW newborns (< 1,500 g and/or < 32 weeks of gestational age).
Short and long-term effects of experimental varicocele.
Andrology
January 2025
Department of Surgery, Division of Urology, Human Reproduction Section, São Paulo Federal University, São Paulo, Brazil.
Background: Varicocele is associated with a progressive decrease in male fertile potential, but it has yet to be determined if the duration of varicocele is associated with altered sperm functional quality.
Objectives: This experimental study investigated the time-dependent effects of varicocele on spermatogenesis, sperm parameters, and sperm functional traits.
Materials And Methods: Thirty-five mature male Wistar rats (200 ± 25 g) were included.
Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema.
Int J Retina Vitreous
January 2025
Army Hospital Research & Referral, Delhi Cantt, New Delhi, Delhi, 110010, India.
Background: Management of Diabetic Macular edema (DME) requires repeated injections. Therefore newer Anti-VEGFs like Brolucizumab with longer durability have been introduced. We compared two different dosages of Brolucizumab, 6.
View Article and Find Full Text PDFDetermining timeframes to death for imminently dying patients: a retrospective cohort study.
BMC Palliat Care
January 2025
Caring Futures Institute, Flinders University, Sturt Rd, Bedford Park, Adelaide, South Australia, 5042, Australia.
Background: Clinicians are frequently asked 'how long' questions at end-of-life by patients and those important to them, yet predicting timeframes to death remains uncertain, even in the last weeks and days of life. Patients and families wish to know so they can ask questions, plan, make decisions, have time to visit and say their goodbyes, and have holistic care needs met. Consequently, this necessitates a more accurate assessment of empirical data to better inform prognostication and reduce uncertainty around time until death.
View Article and Find Full Text PDF"Expectancy-Mood Neural Dynamics Predict Mechanisms of Short- and Long-Term Antidepressant Placebo Effects".
Biol Psychiatry Cogn Neurosci Neuroimaging
January 2025
Department of Psychiatry, University of Pittsburgh. Electronic address:
Objective: Acute experimental models of antidepressant placebo effects suggest that expectancies, encoded within the salience network (SN), are reinforced by sensory evidence and mood fluctuations. However, whether these dynamics extend to longer timescales remains unknown. To answer this question, we investigated how SN and default mode network (DMN) functional connectivity during the processing of antidepressant expectancies facilitates the shift from salience attribution to contextual cues in the SN to belief-induced mood responses in the DMN, both acutely and long-term.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!